According to the American Lung Association, the national five-year lung cancer survival rate is about 29.7 percent. The ...

Amini: I believe this is critical for all stages of NSCLC. Whether you are in a small rural practice, large community or ...

Amini: The systemic landscape is constantly changing and is very exciting. It will only become more complicated for our ...

A new wave of immuno-therapies is reshaping the fight against cancer, turning the body’s own immune system into a powerful ...

Findings from a study led by researchers at The Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

A new study finds Black Medicare beneficiaries with early-stage non–small cell lung cancer (NSCLC) continues to receive curative treatment at lower rates than White patients, highlighting ongoing ...

Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond ...

Theralase Technologies (TSXV:TLT) has shown in pre-clinical trials that its flagship Rutherrin, when activated by X-Ray, is more effective in the treatment of muscle-invasive bladder cancer than ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

SHANGHAI, March 6, 2026 /CNW/ -- Jiahui International Cancer Center (JICC) has stabilized a U.S. patient with advanced non‑small cell lung cancer (NSCLC) and Parkinson's disease using ivonescimab, a ...